Replimune Group (NASDAQ:REPL – Get Free Report) and MiNK Therapeutics (NASDAQ:INKT – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, earnings, profitability, dividends, valuation and analyst recommendations.
Volatility & Risk
Replimune Group has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500. Comparatively, MiNK Therapeutics has a beta of 0.05, indicating that its stock price is 95% less volatile than the S&P 500.
Analyst Ratings
This is a summary of current recommendations and price targets for Replimune Group and MiNK Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Replimune Group | 0 | 0 | 5 | 1 | 3.17 |
| MiNK Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
Earnings & Valuation
This table compares Replimune Group and MiNK Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Replimune Group | N/A | N/A | -$215.79 million | ($3.05) | -3.62 |
| MiNK Therapeutics | N/A | N/A | -$22.46 million | ($0.39) | -1.77 |
Replimune Group is trading at a lower price-to-earnings ratio than MiNK Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Replimune Group and MiNK Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Replimune Group | N/A | -53.12% | -41.49% |
| MiNK Therapeutics | N/A | N/A | -189.14% |
Institutional & Insider Ownership
92.5% of Replimune Group shares are held by institutional investors. Comparatively, 2.9% of MiNK Therapeutics shares are held by institutional investors. 8.8% of Replimune Group shares are held by company insiders. Comparatively, 19.7% of MiNK Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
About Replimune Group
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
About MiNK Therapeutics
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.
